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Abstract Lipoprotein lipase (LPL) plays a central role in lipid
metabolism and transport by catalysing the hydrolysis of
triacylglycerol-rich lipoproteins. The importance of LPL ex-
pressed by the adipose tissue and muscles in the provision of non-
esterified fatty acids and 2-monoacylglycerol for tissue utilisa-
tion is well established. However, recent studies on LPL
expressed by cells of the vascular wall, particularly macrophages,
have identified additional actions of the enzyme that contribute
to the promotion of foam cell formation and atherosclerosis. This
review deals with the role of LPL in atherosclerosis, and its
regulation by mediators that are known to be present in the
lesion.
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1. Introduction
Atherosclerosis, the underlying cause of heart attacks,
strokes and peripheral vascular disease, is directly responsible
for over 50% of all deaths in the USA, Europe and some parts
of Asia [1]. The disease develops slowly over many years in
the intima, the innermost, luminal part of the artery, with the
lesions (plaques) characterised by a proliferation of smooth
muscle cells, extensive accumulation of connective tissue ma-
trix and lipid deposition. These events eventually result in the
occlusion of the artery and, as a consequence, an increase in
the likelihood of the clinical complications mentioned above
(see [2^4] for reviews).
Initially, the process is hypothesised to be a protective
mechanism triggered by damage to the arterial endothelium
[2^4]. This may then become dysfunctional and undergo alter-
ations in permeability, adhesive properties and growth stim-
ulatory characteristics. Release of growth regulatory mole-
cules and chemoattractants by the damaged endothelium
leads to the attachment of monocytes [5], which enter the
subendothelium and mature to macrophages. Macrophages
may then transform into so-called foam cells through the
accumulation of lipids [2^4], a de¢ning early event in the
development of the atherosclerotic lesion. Elucidation of the
mechanisms that are responsible for the transformation of
macrophages into foam cells has, consequently, been the sub-
ject of intense research and has resulted in the identi¢cation of
novel roles for the enzyme lipoprotein lipase (LPL).
The importance of LPL in the regulation of overall lipid
metabolism and transport in humans and other animals is well
documented [6^8]. LPL is expressed by the parenchymal cells
of several extrahepatic tissues and catalyses the hydrolysis of
the triacylglycerol component of chylomicrons and very low
density lipoproteins (VLDL), thereby providing non-esteri¢ed
fatty acids and 2-monoacylglycerols for tissue utilisation [6^8].
Because the circulating lipoproteins are, in general, too large
to cross the vascular endothelium intact, the physiological site
of LPL action is the luminal surface of the vascular endothe-
lial cells, to which the enzyme is attached via highly charged
membrane bound chains of heparan sulphate proteoglycans
(HSPG) [6^8]. Although adipose tissue and muscle parenchy-
mal cells are the major source of LPL synthesis [6^8], from
where the mature enzyme is secreted and transported to the
vascular endothelium, LPL is also expressed and secreted by
macrophages. It is this source of LPL that has been implicated
to play a major role in the pathogenesis of atherosclerosis and
forms the basis of this review. Paradoxically, evidence also
exists in support of an anti-atherogenic role for LPL,
although this relates mainly to the enzyme expressed by the
adipose tissue. Data supporting this involvement will also be
presented.
2. The pro-atherogenic action of LPL
The ¢rst theory implicating LPL in atherosclerosis was pro-
posed by Zilversmit in 1973 [9]. He postulated that high local
concentrations of cholesterol-rich remnants, produced by the
action of LPL on VLDL and chylomicrons at the vascular
endothelium, would be taken up into the arterial wall and
thus lead to the deposition of cholesterol. Supporting this
proposition, LPL de¢ciency in humans, a common genetic
cause of chylomicronaemia syndrome, results in very low plas-
ma levels of low density lipoprotein (LDL) cholesterol and is
believed to cause resistance to premature atherosclerosis [10].
A great deal of more research has been undertaken recently
towards testing Zilversmit’s pioneering hypothesis and is pre-
sented below.
2.1. LPL is expressed in the atherosclerotic lesion
Although LPL is known to be expressed by both macro-
phages and smooth muscle cells, detailed immunocytochemi-
cal and in situ hybridisation experiments have demonstrated
that macrophage-derived foam cells are the primary source of
the enzyme within the atherosclerotic lesion [11,12]. In order
to investigate the possibility that variations in macrophage
LPL synthesis and secretion might constitute a hereditary
component of atherosclerosis, Renier and co-workers [13]
evaluated LPL gene expression and secretion in macrophages
obtained from inbred mouse strains di¡ering in their suscept-
ibility to diet-induced atherosclerosis. Their important ¢nd-
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ings were that macrophages isolated from atherosclerosis-sus-
ceptible mice showed a two- to three-fold higher basal LPL
mass, activity and mRNA levels than those from atheroscle-
rosis-resistant mice, thereby suggesting a contributive role for
LPL in the progression of atherosclerosis. Semenkovich et al.
[14] have demonstrated that although feeding an atherogenic
diet to heterozygous LPL-de¢cient mice results in a more
profound dyslipidaemia due to an increase in non-high density
lipoprotein (HDL) lipoproteins, no di¡erences were seen in
the atherosclerotic lesion area, thereby indicating that the
detrimental e¡ects of dyslipidaemia may be in£uenced by pos-
sibly positive e¡ects of decreased LPL expression in the vas-
cular wall. The signi¢cance of these ¢ndings becomes more
apparent when one considers a very recent and elegant study
by Babaev et al. [15] in which mice chimeric for the expression
of macrophage LPL were produced by the transplant of
LPL3=3, LPL3= or LPL= foetal liver cells, the predomi-
nant site of haematopoiesis in mammalian embryogenesis,
into irradiated female mice. These mice were fed an identical
atherosclerotic diet for 19 weeks, killed and their atheroscler-
otic lesion surface area was measured. The mean lesion area
was reduced by 55% in LPL-de¢cient mice when compared to
mice homozygous for macrophage LPL expression, and by
45% when compared with the heterozygous genotype. These
data imply that, in the setting of an atherogenic diet, macro-
phage LPL expression promotes foam cell formation and
atherosclerosis in vivo. As foam cells are characterised as
lipid-laden macrophages, a pro-atherogenic e¡ect of macro-
phage LPL is likely to be on the uptake of lipids, and this
forms the focus of the next section.
2.2. LPL induces the formation of atherogenic lipoprotein
remnants
LPL bound to the arterial surface has been shown to medi-
ate the lipolysis of circulating VLDL and chylomicron par-
ticles, thereby leading to both a decrease in their size and an
enrichment in their cholesteryl ester content [16]. Studies, in
vitro, have shown that such remnants are taken up readily by
macrophages [17]. Additionally, the free fatty acids produced
by the action of LPL can be re-esteri¢ed by macrophages [18].
The overall outcome of these processes is the net accumula-
tion of cholesteryl esters within the macrophage [17^19] and
their consequent transformation into foam cells.
LPL-mediated hydrolysis of VLDL also produces LDL,
arguably the major contributor to the development of athero-
sclerotic lesions [20,21]. Frequently, these LDL molecules are
oxidised in the intimal space by free radicals which, along
with other modi¢cations, increases their rate of uptake into
macrophages through the scavenger receptors and thereby
promotes further foam cell formation [20,21]. Oxidised LDL
also has additional pro-atherogenic properties, including its
ability to act as a chemoattractant for monocytes [22] and
to mediate endothelial cytotoxicity [23].
This section has demonstrated how the catalytic actions of
LPL can modulate the progression of atherosclerosis. The
process is further promoted by an additional novel feature
of LPL that is independent of its lipolytic action ^ its ability
to act as a pro-atherogenic ligand and this is discussed below.
2.3. LPL acts as an atherogenic ligand
The ability of LPL to facilitate cellular uptake of lipopro-
teins independent of its catalytic properties was ¢rst suggested
in 1975 [24] following the observation that LPL molecules
remain associated with chylomicrons after hydrolysis and
might assist in the hepatic uptake of remnants. Interest in
this hypothesis was revived when Beisiegel and co-workers
showed that LPL was a ligand for the LDL receptor-related
protein (LRP) [25]. Subsequent studies have not only identi-
¢ed other ligands for LPL, but also demonstrated that the
enzyme associates with lipoproteins and promotes their bind-
ing to HSPG, LRP, the LDL receptor and the VLDL receptor
[26^33]. Furthermore, the interaction of LDL with LPL is
increased markedly by its oxidation [34^36] and the enzyme
has also been shown to act synergistically with sphingomye-
linase in the lesion to enhance the association of LDL and the
highly atherogenic lipoprotein (a) to the vascular wall [37].
The net result of all these actions is the retention and accu-
mulation of lipoproteins in the arterial subendothelial matrix
and their rapid uptake by cells via both receptor- and non-
receptor-mediated pathways [30^32,38]. This, along with the
cellular uptake of potential lipolytic products, would promote
the transformation of macrophages into foam cells [17^
19,26,27,38].
In all the examples cited above, LPL appears to act as a
molecular bridge because of its ability to bind both lipopro-
teins and proteoglycans/receptors simultaneously via separate
domains (see [26,38]). This bridging function of LPL, which
has been supported by numerous tissue culture studies [24^
38], has been con¢rmed in vivo recently by Merkel et al. [39]
who showed that transgenic mice expressing catalytically in-
active LPL in muscles could still bind to proteoglycans and
induce the uptake of VLDL. A further variation on this bridg-
ing theme involves cells rather than lipoproteins. For example,
LPL has been shown to function as a monocyte adhesion
protein probably by forming a ‘bridge’ between the arterial
subendothelial matrix and monocyte surface HSPG [40,41].
3. The anti-atherogenic e¡ects of LPL
As mentioned in Section 1, a paradox exists regarding LPL
expression and atherosclerosis. Not only does the enzyme me-
diate atherogenic events in the vessel wall, it also plays a
generalised anti-atherogenic role, as shown by a variety of
experimental evidence. Firstly, Benlian et al. [42] have shown
recently that several LPL-de¢cient patients develop relatively
advanced atherosclerosis. Additionally, individuals who are
heterozygous for LPL mutations that reduce enzymatic activ-
ity have been reported to be predisposed to premature athero-
sclerosis [43^47]. Conversely, a variant of LPL that is associ-
ated with increased activity has been shown to confer
protection against coronary heart disease [48]. Secondly, the
hypertriglyceridaemia that is associated with insulin resistance
and type II diabetes and which is implicated in the ensuing
acceleration of atherosclerosis is mediated largely via the sup-
pression of adipose tissue LPL expression by cytokines such
as tumour necrosis factor-K (TNF-K) and interleukin (IL)-6
[49,50]. Thirdly, e⁄cient lipolysis of triglyceride-rich lipopro-
teins in adipose tissue, heart and skeletal muscle generally
drives the pro¢le of circulating lipoproteins in a non-athero-
genic direction [51^56]. For example, overexpression of LPL is
highly e¡ective in normalising the atherosclerotic lipoprotein
pro¢les of both apoE-de¢cient and LDL receptor-de¢cient
mice and protects wild-type mice against diet-induced hyper-
lipidaemia [51^55]. Additionally, administration of the com-
FEBS 22928 18-11-99
J.R. Mead et al./FEBS Letters 462 (1999) 1^62
pound NO-1886, which increases tissue LPL activity, protects
against atherosclerosis due to elevation of HDL [56]. HDL
has a dual anti-atherogenic e¡ect: it functions as a removal
vehicle for cholesterol, transporting it away from areas of
production to the liver where it can be excreted as bile salts
and, in addition, it has been shown to prevent the oxidation
of LDL by metal ions [57,58]. It is therefore likely that the
role of LPL in atherogenesis may depend on the tissue in
which it is expressed. In the arterial wall, LPL may be pro-
atherogenic whereas in muscle and adipose tissue it may func-
tion protectively.
4. Regulation of LPL by agents present in the lesion
As detailed above, the expression of LPL within the vessel
wall, especially by macrophages, is likely to be pro-atherogen-
ic. During the development of atherosclerosis, cellular changes
in the vascular wall are regulated by many factors, including
modi¢ed lipoproteins, growth factors, chemotactic factors and
cytokines, all of which may be present in the lesion (see [2^4]).
The e¡ect of such factors on macrophage LPL expression is,
therefore, likely to make a major contribution to the modu-
lation of the atherosclerotic process. Unfortunately, until re-
cently, several studies on the regulation of macrophage LPL
expression have produced incomplete and often con£icting
results [59^62]. This has been attributed, at least in part, to
aspects of experimental design, such as the origin and status
of the cells, their culture conditions, the concentration of me-
diator used and the time course of the observations. We have,
however, recently carried out a systematic and detailed anal-
ysis of the regulation of macrophage LPL by lipopolysacchar-
ide (LPS) and several cytokines, either singly or in combina-
tion, using a range of macrophage cell lines from di¡erent
species [63^68]. Although LPS, IL-1, IL-11, interferon-Q
(IFN-Q) and TNF-K suppressed macrophage LPL activity,
mRNA levels and protein content, IL-6 and leukocyte inhib-
itory factor had no e¡ect. These responses showed several
di¡erences to those described previously for adipocytes
[7,8,63], thereby suggesting the existence of potential cell-spe-
ci¢c mechanisms for the regulation of LPL gene expression by
such mediators. Because interactions amongst mediators have
been found to be more important in the initiation and pro-
gression of diseases, including atherosclerosis, rather than the
presence or absence of any given e¡ector [69], we have ex-
tended our studies to the use of paired combinations of medi-
ators. Several novel interactions in the regulation of macro-
phage LPL expression have been identi¢ed, of which the most
striking was the strong synergism between IFN-Q and TNF-K
or LPS [64,68]. Such a synergism was also observed when the
cells were exposed sequentially ¢rst to IFN-Q and then to
Fig. 1. Possible sites and potential mechanisms for the regulation of macrophage LPL by mediators that are known to be present in the athero-
sclerotic lesion. The mechanisms by which the mediators activate (+) or inhibit (3) the expression and/or activity of LPL are shown along with
the regulation of nitric oxide synthetase and TNF-K by LPL. See text for more details; references are indicated in parentheses. Abbreviations:
AP-1, activator protein-1; GR, glucocorticoid receptor; IFN-Q, interferon-gamma; LPS, lipopolysaccharide; M-CSF, macrophage colony-stimu-
lating factor; OBP, octamer binding protein(s); NF-UB, nuclear factor kappa B; OxLDL, oxidised LDL; PDGF, platelet-derived growth fac-
tor; PG, prostaglandins; PI3K, phosphatidylinositol 3P-kinase; PKC, protein kinase C; PPAR, peroxisome proliferator-activated receptor;
ROI, reactive oxygen intermediates; TK, tyrosine kinase; TNF-K, tumour necrosis factor-K.
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TNF-K or LPS, thereby suggesting a potential priming action
of IFN-Q [64,68]. Other agents that have also been shown to
suppress macrophage LPL expression include prostaglandins
[70], oxidised LDL ([71] ; our unpublished observations) and
biologically active lipids that are known to form during LDL
oxidation, such as lysophosphatidylcholine [71], 7L-hydroxy-
cholesterol [71,72] and 25-hydroxycholesterol [72]. Because
cytokines, oxidised LDL and biologically active lipids are gen-
erally considered to be pro-atherogenic, the precise signi¢-
cance of their suppressing action on macrophage LPL gene
expression (i.e. an anti-atherogenic event) is currently unclear.
It is, however, possible that they may limit the transformation
of macrophages into foam cells during the initial stages of
vascular damage until their actions are over-ridden by other
changes in the composition and concentration of e¡ectors,
particularly LPL-elevating factors, in the local milieu of me-
diators as the progression of the disease occurs.
Many e¡ectors have been identi¢ed recently that increase
macrophage LPL expression, including hydrogen peroxide
(oxidant stress/reactive oxygen species), dexamethasone, glu-
cose, platelet-derived growth factor (PDGF) and macrophage
colony-stimulating factor [73^77]. Pro-atherogenic actions for
these factors have also been identi¢ed from other lines of
evidence. For example, MCP-1 is found in human atheroma
and mice lacking the corresponding gene are less susceptible
to atherosclerosis and have fewer monocytes in any vascular
lesions that form [78]. Additionally, both glucose and ad-
vanced glycation products have been suggested to make a
major contribution to the unusually high incidence of athero-
sclerosis in diabetic patients [79]. Furthermore, elevated pro-
duction of reactive oxygen intermediates (ROI) in the early
atherosclerotic lesion has been implicated in the oxidation of
LDL, activation of macrophages and modulation of the ac-
tion of several mediators that are involved in their cellular
proliferation and di¡erentiation [80].
5. Concluding remarks
Given the pivotal role of LPL in the pathogenesis of athe-
rosclerosis, studies aimed at elucidating the molecular mech-
anisms that are responsible for the regulation of macrophage
LPL expression are clearly essential for the identi¢cation of
potential important targets for therapeutic intervention. Fig. 1
summarises the current state of knowledge on the molecular
basis of macrophage LPL expression, and clearly indicates a
lack of clarity in our understanding of the mechanisms in-
volved. Thus, with respect to intracellular signalling, protein
kinase C has been shown to be involved, at least in part, in
the induction of macrophage LPL expression by glucose,
PDGF and ROI [73,75,76], cAMP for the suppression by
prostaglandins [70] and we have identi¢ed that both the ty-
rosine kinase and the phosphatidylinositol 3P-kinase signal
transduction pathways are involved in the LPS and cytokine
responses [81]. Although the regulation of LPL expression by
cytokines, glucose and ROI is mediated mainly at the tran-
scriptional level [65,73,75], the cis-acting regulatory elements
and the trans-acting factors remain to be identi¢ed. A poten-
tial role for the activator protein-1 (AP-1) family of transcrip-
tion factors in the regulation of the glucose response has been
implied from the partial inhibition observed when cells were
incubated with an antisense oligonucleotide against c-fos, a
member of the AP-1 family [75]. Furthermore, the binding
of AP-1 to a site present in the murine LPL promoter was
increased when extracts from cells exposed to glucose were
used [75]. Additionally, exposure of J774 macrophages to
LPS induces the binding of proteins to the octamer binding
motif present in the LPL promoter, and may be involved in
the suppression of gene transcription [82]. However, the most
direct evidence of the underlying mechanisms whereby factors
involved in the regulation of LPL gene expression operate, in
the context of atherosclerosis, relates to studies on the role of
the peroxisome proliferator-activated receptors (PPAR) [83].
These receptors belong to the nuclear receptor superfamily of
transcription factors that heterodimerise with the retinoid X
receptor, and regulate gene expression in response to the bind-
ing of ligands such as 15-deoxy-v12;14-prostaglandin J2, certain
polyunsaturated fatty acids and thiazolidinedione antidiabetic
drugs (see [84,85] for reviews). Both PPARK and PPARQ have
been shown to induce LPL gene transcription in response to a
range of such ligands [83]. PPARK is expressed by monocytes
and PPARQ appears only during the di¡erentiation of mono-
cytes into macrophages [86]. Furthermore, PPARQ is ex-
pressed at high levels in macrophage-derived foam cells of
human atherosclerotic lesions in a pattern that shows a strong
positive correlation with the presence of oxidation-derived
epitopes and, additionally, its expression is induced by oxi-
dised LDL both in primary macrophage cultures and mono-
cytic cell lines [87,88]. Surprisingly, although the LPL mRNA
levels and protein mass in macrophages are induced by a
variety of PPAR activators, the LPL activity was found to
decrease in all cases [86]. This suggests that PPAR activating
agents prevent the formation of active enzyme or its secretion,
and could involve either defects in the post-translational proc-
essing of the protein [89] or activation of inhibitor(s) of LPL
activity. It has been suggested that apoE, which has been
shown to inhibit LPL activity in vitro, could represent such
an inhibitor that could counteract the pro-atherogenic e¡ect
of LPL in the arterial wall [86].
Finally, a further novel role for LPL has been identi¢ed,
that is as a regulator of macrophage gene expression and
protein secretion. Renier and co-workers were the ¢rst to
show that LPL induces the expression of the TNF-K gene at
the level of both gene transcription and mRNA stability [90].
This induction of TNF-K production by LPL is increased
during the di¡erentiation of monocytes into macrophages,
occurs via a protein kinase C-dependent pathway and is medi-
ated through cell surface proteoglycans [91]. LPL has also
been shown to synergise with IFN-Q in the induction of mac-
rophage nitric oxide synthetase mRNA expression at the tran-
scriptional level [92]. More recently, LPL has been identi¢ed
to reduce the secretion of apoE from macrophages [93]. Given
the importance of TNF-K, nitric oxide and apoE in the patho-
genesis of atherosclerosis, this novel role of LPL and the
corresponding mechanisms need to be investigated further.
In conclusion, substantial experimental evidence indicates a
key role for LPL expressed by the arterial wall in the patho-
genesis of atherosclerosis, and this involves multiple actions of
the enzyme, including lipolysis, bridging and regulation of
gene expression. However, the mechanisms that are responsi-
ble for the regulation of LPL expression and secretion by cells
of the vascular wall, particularly macrophages, during the
progression of the disease by factors present in the lesion
remain ill de¢ned. We feel that this area should form the focus
of intense research, particularly given the existence of multiple
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factors that suppress macrophage LPL expression and a good
correlation between mediators that induce macrophage LPL
expression and their ability to accelerate the atherosclerotic
process (e.g. glucose and growth factors). Success in these
endeavours should allow the identi¢cation of novel targets
for therapeutic intervention and prevention.
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